Improvements in gait and balance in patients with multiple sclerosis after treatment with coconut oil and epigallocatechin gallate. A pilot study

Cuerda-Ballester, María; Proaño, Belén; Alarcón-Jiménez, Jorge; Bernardo, Nieves de; Villarón-Casales, Carlos; Romance, Jose María Lajara; Ortí, José Enrique de la Rubia

doi:10.1039/d2fo02207a

Cited by 12 publications

(7 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the existing literature, HDL levels, specifically through the action of Apo A1, are related to myelin improvement [57], as well as an increase in oligodendrogenesis, axonal regeneration [58], and reduced extravasation of immune cells in the CNS, which implies a decrease in inflammation at the central level [59]. All these mechanisms involving HDL could, in turn, help to explain the improvement in walking capacity already evidenced in our laboratory by the IG group; specifically, the increase in walking speed (10MWT), which is the variable that improves only in this group [60] and is negatively associated with HDL values in our population sample before the intervention (Table S1).…”

Section: Discussionmentioning

confidence: 81%

Lipid Profile in Multiple Sclerosis: Functional Capacity and Therapeutic Potential of Its Regulation after Intervention with Epigallocatechin Gallate and Coconut Oil

de la Rubia Ortí,

Platero Armero,

Cuerda-Ballester

et al. 2023

Foods

Self Cite

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) patients present dyslipidemia and functional disability. Epigallocatechin gallate (EGCG) and coconut oil have been shown to be effective against dyslipidemia. Objective: To analyze the relationship between lipid profiles, fat consumption, and functional disability in patients with MS after administering EGCG and coconut oil. Methods: A four-month pilot study was conducted on 45 MS patients, divided into an intervention group (IG) and a control group (CG). The IG received 800 mg of EGCG and 60 mL of coconut oil. Lipid profiles were measured before and after the intervention, along with other data such as dietary habits, inflammatory markers, and functional capacity. Results: Dyslipidemia did not correlate with the patients’ fat consumption. After the intervention, triglycerides (TG) levels were lower in IG compared to CG. This decrease was positively correlated with an improvement in functional disability (determined by the Expanded Disability Status Scale (EDSS)) and negatively with high-density cholesterol (HDL) and apolipoprotein A1. Significant and positive correlations were observed between EDSS and C-reactive protein (CRP) in the IG. These changes in the IG could be related to body fat decrease, whose percentage shows a positive correlation with CRP and TG levels, and a negative correlation with HDL levels. Conclusions: Patients with MS present a certain type of dyslipemia not associated with their nutritional habits. The administration of EGCG and coconut oil seems to decrease blood TG levels, which could explain the functional improvements.

show abstract

Section: Discussionmentioning

confidence: 81%

Lipid Profile in Multiple Sclerosis: Functional Capacity and Therapeutic Potential of Its Regulation after Intervention with Epigallocatechin Gallate and Coconut Oil

de la Rubia Ortí,

Platero Armero,

Cuerda-Ballester

et al. 2023

Foods

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cuerda-Ballester et al. ( 379 ) conducted a pilot study involving 51 MS patients to examine the effects of treatment with coconut oil and EGCG on gait and balance. Participants were randomly assigned to either an intervention group or a control group.…”

Section: Contemporary Approaches In Clinical Trials For Managing Neur...mentioning

confidence: 99%

Immunological dimensions of neuroinflammation and microglial activation: exploring innovative immunomodulatory approaches to mitigate neuroinflammatory progression

Fornari Laurindo,

Aparecido Dias,

Cressoni Araújo

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The increasing life expectancy has led to a higher incidence of age-related neurodegenerative conditions. Within this framework, neuroinflammation emerges as a significant contributing factor. It involves the activation of microglia and astrocytes, leading to the release of pro-inflammatory cytokines and chemokines and the infiltration of peripheral leukocytes into the central nervous system (CNS). These instances result in neuronal damage and neurodegeneration through activated nucleotide-binding domain and leucine-rich repeat containing (NLR) family pyrin domain containing protein 3 (NLRP3) and nuclear factor kappa B (NF-kB) pathways and decreased nuclear factor erythroid 2-related factor 2 (Nrf2) activity. Due to limited effectiveness regarding the inhibition of neuroinflammatory targets using conventional drugs, there is challenging growth in the search for innovative therapies for alleviating neuroinflammation in CNS diseases or even before their onset. Our results indicate that interventions focusing on Interleukin-Driven Immunomodulation, Chemokine (CXC) Receptor Signaling and Expression, Cold Exposure, and Fibrin-Targeted strategies significantly promise to mitigate neuroinflammatory processes. These approaches demonstrate potential anti-neuroinflammatory effects, addressing conditions such as Multiple Sclerosis, Experimental autoimmune encephalomyelitis, Parkinson’s Disease, and Alzheimer’s Disease. While the findings are promising, immunomodulatory therapies often face limitations due to Immune-Related Adverse Events. Therefore, the conduction of randomized clinical trials in this matter is mandatory, and will pave the way for a promising future in the development of new medicines with specific therapeutic targets.

show abstract

“…The clinical trial results obtained in the last ten years of research indicate the beneficial influence of EGCG on the human body. Studies have focused on the influence of this phenolic compound on amyloidosis [ 278 ] atherosclerosis [ 279 ], cystic fibrosis [ 280 , 281 ], Barrett’s oesophagus [ 282 ], diabetes [ 283 , 284 , 285 ], Down’s syndrome [ 286 , 287 , 288 , 289 ], dystrophic epidermolysis bullosa [ 290 ], hypertension [ 291 , 292 ], multiple sclerosis [ 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 ], obesity [ 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 ], radiation-induced esophagitis [ 309 , 310 , 311 , 312 ], and ulcerative colitis [ 313 ].…”

Section: Egcg In Cancer Prevention and Therapy?mentioning

confidence: 99%

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications

Kciuk,

Alam,

Ali

et al. 2023

Molecules

View full text Add to dashboard Cite

Cellular signaling pathways involved in the maintenance of the equilibrium between cell proliferation and apoptosis have emerged as rational targets that can be exploited in the prevention and treatment of cancer. Epigallocatechin-3-gallate (EGCG) is the most abundant phenolic compound found in green tea. It has been shown to regulate multiple crucial cellular signaling pathways, including those mediated by EGFR, JAK-STAT, MAPKs, NF-κB, PI3K-AKT-mTOR, and others. Deregulation of the abovementioned pathways is involved in the pathophysiology of cancer. It has been demonstrated that EGCG may exert anti-proliferative, anti-inflammatory, and apoptosis-inducing effects or induce epigenetic changes. Furthermore, preclinical and clinical studies suggest that EGCG may be used in the treatment of numerous disorders, including cancer. This review aims to summarize the existing knowledge regarding the biological properties of EGCG, especially in the context of cancer treatment and prophylaxis.

show abstract

Improvements in gait and balance in patients with multiple sclerosis after treatment with coconut oil and epigallocatechin gallate. A pilot study

Abstract: Multiple sclerosis (MS) is a neurodegenerative disease that progressively decreases the muscular and functional capacity.

Cited by 12 publications

References 74 publications

Lipid Profile in Multiple Sclerosis: Functional Capacity and Therapeutic Potential of Its Regulation after Intervention with Epigallocatechin Gallate and Coconut Oil

Lipid Profile in Multiple Sclerosis: Functional Capacity and Therapeutic Potential of Its Regulation after Intervention with Epigallocatechin Gallate and Coconut Oil

Immunological dimensions of neuroinflammation and microglial activation: exploring innovative immunomodulatory approaches to mitigate neuroinflammatory progression

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications

Contact Info

Product

Resources

About